Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

Core Insights - Roche announced positive topline results from the Phase II ZUPREME-1 trial for petrelintide, showing significant weight loss in participants with obesity [1][2][3] Group 1: Trial Results - The trial involved 493 participants with a mean BMI of 37 kg/m², achieving up to 10.7% mean weight loss from baseline after 42 weeks compared to 1.7% with placebo [2][9] - Petrelintide demonstrated a favorable tolerability profile, with a treatment discontinuation rate of 4.8% due to adverse events, comparable to 4.9% for placebo [3][8] - Female participants experienced greater weight loss than male participants during the trial [2] Group 2: Future Developments - Final data from ZUPREME-1, including a nine-week safety follow-up, will be presented at a medical congress to inform Phase III trial designs [4] - Topline results from the second Phase II trial, ZUPREME-2, are expected in the second half of 2026, focusing on individuals with obesity and type 2 diabetes [4] - A Phase II trial exploring the combination of petrelintide and CT-388 will be initiated later in 2026 [4] Group 3: Company Background and Strategy - Roche is advancing a cardiometabolic portfolio to address the diverse needs of individuals living with obesity and its comorbidities [5] - The global obesity epidemic is projected to affect over four billion people by 2035, increasing the burden on healthcare systems [6] - Roche entered into a collaboration with Zealand in 2025 to co-develop and commercialize petrelintide for obesity management [7]